Skip to main content

Search

Show all results for

Home

Person

Tamara Maric

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (8)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD plus metabolism

Elena Goun, Pavlo Khodakivskyi, Arkadiy Bazhin, Aleksey Yevtodiyenko, Tamara Maric, Georgy Mikhaylov

Nicotinamide riboside (NR) is a form of vitamin B3 and is one of the most studied compounds for the restoration of cellular NAD+ levels demonstrating clinical potential in many metabolic and age-related disorders. Despite its wide commercial availability a ...

ELSEVIER ADVANCED TECHNOLOGY2023

Phage Display Selected Cyclic Peptide Inhibitors of Kallikrein-Related Peptidases 5 and 7 and Their In Vivo Delivery to the Skin

Christian Heinis, Luc Reymond, Alessandro Zorzi, Patrick Andreas Gonschorek, Mischa Schüttel, Vanessa Carle, Tamara Maric

Kallikrein-related peptidases 5 (KLK5) and 7 (KLK7) are serine proteases with homeostatic functions in the epidermis that play a critical role in Netherton syndrome (NS), a rare yet life-threatening genetic disorder that currently lacks specific treatment. ...

AMER CHEMICAL SOC2022

Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation

Christian Heinis, Chloé Rogg, Xudong Kong, Vanessa Carle, Cristina Diaz Perlas, Camille Villequey, Tamara Maric, Kaycie Marie Butler, Christina Lamers

Coagulation factor XI (FXI) has emerged as a promising target for the development of safer anticoagulation drugs that limit the risk of severe and life-threatening bleeding. Herein, we report the first cyclic peptide-based FXI inhibitor that selectively an ...

2021